Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674369 | 0.86 | MEN1 (0.40) | MAPTMEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL7668551 | 0.85 | DRD2 (0.50) | MEN1KMT2ADRD4 | |
| SCHEMBL7666257 | 0.83 | SIGMAR1 (0.39) | MAPTMEN1KMT2ADRD4TDP1 | |
| SCHEMBL7671274 | 0.78 | TAAR1 (0.43) | SLC6A4 | |
| SCHEMBL19321713 | 0.75 | CYP1A2 (0.45) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8804326 | 0.75 | CYP1A2 (0.45) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1445116 | 0.75 | MEN1 (0.41) | MEN1KMT2ALMNAPOLBTDP1 | |
| SCHEMBL19111959 | 0.75 | MEN1 (0.41) | MEN1KMT2ALMNAPOLBTDP1 | |
| SCHEMBL996908 | 0.74 | L3MBTL1 (0.50) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18499511 | 0.72 | CYP1A2 (0.39) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395730-B1 | CARDIOVASCULAR DISORDERS | ICAGEN, INC. | 2002-05-28 | — | — | US | disclosed |
| US-6174908-B1 | TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE | ICAGEN, INC. | 2001-01-16 | — | — | US | disclosed |